RxDoctor Payments Data

Rabih Maroun, MD

Internal Medicine · Staten Island, NYNPI 1942408208

Payments from drug & device makers

$76in general payments, 2019–2025

Across 4 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$43
  • United Therapeutics Corporation$20
  • Insmed, Inc.$13

What the payments were for

  • Food & beverage$5674%
  • Education$2026%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$43
United Therapeutics Corporation1$20
Insmed, Inc.1$13

How this compares

$76 in reported general payments places this provider in the 35th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$373,613
Medicare patients
922
Services billed
3,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter311$307,021
Breo ElliptaFluticasone/Vilanterol411$197,851
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr91$53,715
SymbicortBudesonide/Formoterol Fumarate119$34,367
Incruse ElliptaUmeclidinium Bromide68$29,758
Spiriva RespimatTiotropium Bromide28$27,489
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate145$26,644
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$26,511
Albuterol Sulfate HfaAlbuterol Sulfate454$12,594
Fluticasone-SalmeterolFluticasone Propion/Salmeterol67$11,880
Spiriva HandihalerTiotropium Bromide16$11,709
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$10,896
Azelastine Hcl433$7,517
Arnuity ElliptaFluticasone Furoate23$6,724
DuleraMometasone/Formoterol12$5,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$43$595,068904 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →